Learn how the benefits of GLP-1s may be outweighed by the risks.

Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this ...

Investigators examined the comparative effectiveness of SGLT2 inhibitors and GLP-1 receptor agonists in a real-world setting.

A novel oral peptide PN-477o with once-daily dosing, high potency and activation of glucagon-like peptide-1 (GLP-1), ...

Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...

A recent phase III randomized trial found an investigational oral small-molecule GLP-1 receptor agonist significantly ...

GLP-1 drugs alter taste perceptions, challenging food makers to adapt by enhancing umami flavours, balancing sweetness, and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Once everyone’s had enough of injections, side effects, and the vast expense of GLP-1 drugs, it could be natural alternatives ...

Ecnoglutide, a novel glucagon-like peptide-1 (GLP-1) receptor agonist, was significantly more effective than placebo for inducing weight loss in adults with overweight or obesity, based on data ...

Patients with type 2 diabetes had a lower risk of glaucoma when they used glucagon-like peptide 1 (GLP-1) receptor agonists across multiple studies.